TCG Crossover Management
Latest statistics and disclosures from TCG Crossover Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, CGON, TNGX, COGT, CNTA, and represent 44.37% of TCG Crossover Management's stock portfolio.
- Added to shares of these 10 stocks: BCRX (+$105M), VOR (+$97M), MIRM (+$92M), IRON (+$86M), IMVT (+$70M), SRZN (+$43M), IPSC (+$39M), TECX (+$37M), CATX (+$33M), ALXO (+$26M).
- Started 11 new stock positions in IRON, SRZN, AgomAb Therapeutics NV, CGEM, BCRX, TECX, IPSC, ALXO, CATX, VOR. CNTX.
- Reduced shares in these 10 stocks: RAPT (-$88M), ABVX (-$70M), EYPT (-$65M), LQDA (-$49M), TNGX (-$47M), GPCR (-$38M), COGT (-$36M), OCUL (-$35M), AGIO (-$32M), MAZE (-$7.2M).
- Sold out of its positions in AGIO, EYPT, MAZE, RAPT, VTYX.
- TCG Crossover Management was a net buyer of stock by $225M.
- TCG Crossover Management has $3.5B in assets under management (AUM), dropping by 15.68%.
- Central Index Key (CIK): 0001839948
Tip: Access up to 7 years of quarterly data
Positions held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for TCG Crossover Management
TCG Crossover Management holds 49 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa American Depositary Shares Adrs (ABVX) | 20.6 | $722M | -8% | 6.5M | 111.35 |
|
| Cg Oncology Comm (CGON) | 7.1 | $248M | 3.7M | 67.68 |
|
|
| Tango Therapeutics Comm (TNGX) | 6.3 | $220M | -17% | 11M | 20.92 |
|
| Cogent Biosciences Comm (COGT) | 5.4 | $190M | -15% | 4.9M | 38.49 |
|
| Centessa Pharmaceuticals Adrs (CNTA) | 4.9 | $170M | 4.3M | 39.72 |
|
|
| Dianthus Therapeutics Comm (DNTH) | 4.0 | $141M | 1.7M | 83.92 |
|
|
| Tyra Biosciences Comm (TYRA) | 3.6 | $124M | +12% | 3.2M | 38.30 |
|
| Immunovant Comm (IMVT) | 3.2 | $111M | +168% | 4.5M | 24.84 |
|
| Biocryst Pharmaceuticals Comm (BCRX) | 3.0 | $105M | NEW | 11M | 9.52 |
|
| Mirum Pharmaceuticals Comm (MIRM) | 2.8 | $98M | +1611% | 1.1M | 92.38 |
|
| Vor Biopharma Comm (VOR) | 2.8 | $97M | NEW | 5.7M | 17.01 |
|
| Spyre Therapeutics Comm (SYRE) | 2.7 | $96M | 1.9M | 50.44 |
|
|
| Amylyx Pharmaceuticals Comm (AMLX) | 2.5 | $87M | 6.2M | 13.90 |
|
|
| Disc Medicine Comm (IRON) | 2.5 | $86M | NEW | 1.3M | 63.94 |
|
| Dyne Therapeutics Comm (DYN) | 2.4 | $84M | 4.6M | 18.13 |
|
|
| Monte Rosa Therapeutics Comm (GLUE) | 2.2 | $76M | 4.6M | 16.45 |
|
|
| Savara Comm (SVRA) | 1.9 | $68M | 12M | 5.46 |
|
|
| Revolution Medicines Comm (RVMD) | 1.6 | $56M | +32% | 577k | 97.25 |
|
| Kodiak Sciences Comm (KOD) | 1.6 | $55M | 1.4M | 38.12 |
|
|
| Lb Pharmaceuticals Comm (LBRX) | 1.3 | $45M | +5% | 1.8M | 24.62 |
|
| Surrozen Comm (SRZN) | 1.2 | $43M | NEW | 1.5M | 29.13 |
|
| Adc Therapeutics Sa Comm (ADCT) | 1.2 | $43M | 11M | 3.75 |
|
|
| Relay Therapeutics Comm (RLAY) | 1.2 | $43M | +32% | 4.3M | 9.95 |
|
| Fulcrum Therapeutics Comm (FULC) | 1.2 | $40M | 5.3M | 7.67 |
|
|
| Biohaven Comm (BHVN) | 1.1 | $39M | 4.6M | 8.46 |
|
|
| Century Therapeutics Comm (IPSC) | 1.1 | $39M | NEW | 18M | 2.20 |
|
| Tectonic Therapeutic Comm (TECX) | 1.1 | $37M | NEW | 1.2M | 30.91 |
|
| Perspective Therapeutics Comm (CATX) | 0.9 | $33M | NEW | 7.9M | 4.17 |
|
| Xencor Comm (XNCR) | 0.8 | $30M | 2.5M | 12.06 |
|
|
| Entrada Therapeutics Comm (TRDA) | 0.8 | $29M | +9% | 2.3M | 12.62 |
|
| Alx Oncology Holdings Comm (ALXO) | 0.7 | $26M | NEW | 13M | 2.00 |
|
| Arvinas Holding Comm (ARVN) | 0.7 | $25M | -10% | 2.4M | 10.60 |
|
| Janux Therapeutics Comm (JANX) | 0.7 | $25M | 1.8M | 13.90 |
|
|
| Agomab Therapeutics Nv Adrs | 0.6 | $22M | NEW | 2.1M | 10.49 |
|
| Alector Comm (ALEC) | 0.6 | $22M | 10M | 2.15 |
|
|
| Mbx Biosciences Comm (MBX) | 0.6 | $19M | 650k | 29.85 |
|
|
| Silence Therapeutics Adrs (SLN) | 0.5 | $16M | 3.0M | 5.27 |
|
|
| Liquidia Technologies Comm (LQDA) | 0.4 | $15M | -76% | 403k | 37.74 |
|
| Ocular Therapeutix Comm (OCUL) | 0.4 | $14M | -71% | 1.6M | 8.47 |
|
| Avalo Therapeutics Comm (AVTX) | 0.3 | $11M | +52% | 738k | 14.93 |
|
| Urogen Pharma Comm (URGN) | 0.2 | $7.3M | -43% | 405k | 17.98 |
|
| Monopar Therapeutics Comm (MNPR) | 0.2 | $7.2M | -6% | 132k | 54.79 |
|
| Context Therapeutics Comm (CNTX) | 0.2 | $7.0M | NEW | 2.7M | 2.62 |
|
| Structure Therapeutics Adrs (GPCR) | 0.2 | $6.8M | -84% | 140k | 48.20 |
|
| Cullinan Therapeutics Comm (CGEM) | 0.2 | $5.8M | NEW | 407k | 14.21 |
|
| Korro Bio Comm (KRRO) | 0.1 | $4.7M | 416k | 11.32 |
|
|
| Leonabio Comm (LONA) | 0.1 | $4.7M | 464k | 10.05 |
|
|
| Upstream Bio Comm (UPB) | 0.0 | $1.6M | -75% | 181k | 9.00 |
|
| Vistagen Therapeutics Comm (VTGN) | 0.0 | $1.5M | 2.7M | 0.57 |
|
Past Filings by TCG Crossover Management
SEC 13F filings are viewable for TCG Crossover Management going back to 2021
- TCG Crossover Management 2026 Q1 filed May 15, 2026
- TCG Crossover Management 2025 Q4 filed Feb. 17, 2026
- TCG Crossover Management 2025 Q3 filed Nov. 17, 2025
- TCG Crossover Management 2025 Q2 filed Aug. 14, 2025
- TCG Crossover Management 2025 Q1 filed May 14, 2025
- TCG Crossover Management 2024 Q4 filed Feb. 14, 2025
- TCG Crossover Management 2024 Q3 filed Nov. 14, 2024
- TCG Crossover Management 2024 Q2 filed Aug. 14, 2024
- TCG Crossover Management 2024 Q1 filed May 15, 2024
- TCG Crossover Management 2023 Q4 filed Feb. 14, 2024
- TCG Crossover Management 2023 Q3 filed Nov. 14, 2023
- TCG Crossover Management 2023 Q2 filed Aug. 14, 2023
- TCG Crossover Management 2023 Q1 filed May 15, 2023
- TCG Crossover Management 2022 Q4 filed Feb. 14, 2023
- TCG Crossover Management 2022 Q3 filed Nov. 14, 2022
- TCG Crossover Management 2022 Q2 filed Aug. 15, 2022